Lupin

Lupin gets USFDA nod for Ipratropium Bromide Nasal Solution (Nasal Spray), 0.03%

Lupin and Natco Pharma gets USFDA nod for Generic Bosentan tablets

Lupin completes acquisition of 42.61% stake in Sunsure Solarpark

Lupin receives FDA’s EIR for Pithampur Unit-1 manufacturing facility

Stock Market Update, January 2: Lupin, Eicher Motors, IPCA Laboratories, Mahindra & Mahindra and more hit 52-week highs today

Lupin shares jump 2% after company acquires Huminsulin from Eli Lilly

Lupin acquires Huminsulin from Eli Lilly to strengthen its diabetes portfolio

Pharma stocks weekly roundup: Biocon leads with 9.08% gain, Torrent Pharma up 4.91%, Lupin dips 1.82%

Lupin shares in focus as Q2 revenue jumps 12.6% YoY to ₹5,673 crore

Lupin Q2 FY25 Results: Revenue grows 12.6% YoY to ₹5,039 crore, PAT jumps 74.1% YoY

How are these stocks reacting ahead of Q2 results – RVNL, NHPC, Trent, Lupin and more

Lupin and Aurobindo Pharma shares in focus on positive US generics outlook; Macquarie sees potential rally

Lupin launches first generic of Pred Forte in United States

UBS initiates Sell call on Zydus, Dr Reddy’s, Aurobindo Pharma, Lupin

UBS has initiated sell ratings on key Indian pharmaceutical stocks including Zydus, Dr. Reddy's, Aurobindo, and Lupin, citing overestimated core margins and slow growth in their primary markets of India and the US.

BofA Securities cuts target prices for Zydus Life and Lupin shares amid Mirabegron uncertainty